• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Achaogen

edit

Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company’s most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrum efficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance.

Recent Milestones

edit

• 
  Achaogen received $18.9M in Partial Close funding. (3/22/13)
  Posted 6/3/13 at 4:15am via sec.gov
• 
  Achaogen — Achaogen Awarded Contract Worth up to $64 Million by BARDA for the Development of ACHN-490 (8/30/10)
  Posted 9/5/10 at 10:24pm via achaogen.com
• 
  Achaogen received $56M in Series C funding. (4/7/10)
  Posted 4/7/10 at 8:27pm via pr-inside.com
• 
  Achaogen received $26M in Series B funding. (10/10/06)
  Posted 4/21/10 at 12:13am via achaogen.com

Videos

Screenshots

edit

Above: Achaogen
Uploaded: 4/21/10

Sources

1. Achaogen Closes Series B Financing (achaogen.com) [edit]
2. Achaogen Completes $56 Million Series C Financing (pr-inside.com) [edit]
3. SEC (sec.gov) [edit]
Achaogen Awarded Contract Worth up to $64 Million by BARDA for the Development of ACHN-490 (achaogen.com) [edit]